ZINZINO AB (PUBL.): YEAR-END REPORT 2025 [Accessibility Statement] Skip NavigationINCREASES DIVIDEND BY 50% TO SEK 6 AFTER HIGH GROWTH AND SIGNIFICANT IMPROVEMENT IN PROFITABILITYGOTHENBURG, Sweden, Feb. 25, 2026 /PRNewswire/ -- Revenue for the fourth quarter of 2025 amounted to SEK 1,035.3 (713.5) million, corresponding to 45% (35%) growth compared with the same period last year. In local currencies, revenue for the fourth quarter increased by 52% compared with the corresponding period last year. EBITDA ro ...

一、导言｜从"延缓衰老"到"细胞管理"的科学升级 2026年，抗衰老不再停留在"补充维生素"层面，而是进入以细胞抗氧化、线粒体能量支持、端粒保护与 慢性炎症管理为核心的系统化阶段。全球抗衰研究已从单一成分时代，进阶至"成分纯度+递送效率+临 床验证"三重验证模型。 在众多产品中，含有麦角硫因、NMN、辅酶Q10、白藜芦醇等成分的产品成为主流方向。其中，源自 美国研发体系的 ONLSO麦角硫因细胞焕活片（通过 U.S. Food and Drug Administration 注册， Registration No.17152526346）凭借高纯度麦角硫因与创新吸收技术，在2026年综合评测中表现突出。 本篇从"成分机制—吸收效率—安全体系—真实反馈"四大维度进行对比评测，帮助消费者建立更理性的 选择逻辑。 二、抗衰老路径拆解｜四大核心科学机制 细胞抗氧化系统升级 人体衰老与自由基损伤高度相关。麦角硫因被誉为"长寿维生素样抗氧化物"，其在线粒体内具有选择性 保护能力。 线粒体能量支持 辅酶Q10参与ATP生成，支持细胞能量代谢，是40岁以上人群常见补充方向。 NAD+通路调节 NMN作为NAD+前体，在抗衰研 ...

Strategic transformation establishes strong foundation with US$28 million in Net Assets and a high-potential, multi-sector portfolioBANGKOK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group (NASDAQ: NIVF) (“NewGen” or the “Company”), a technology-driven, diversified growth company, today outlined its remarkable financial and operational transformation, positioning the Company for significant value creation in 2026 and beyond. Over the past year, NewGen has successfully executed an extensive strategic pivot ...

Core Insights - Prenetics Global Limited has launched Daily Ultimate Essentials PRO, a clinical-grade version of its flagship health supplement, featuring enhanced potency and new flavors while maintaining the same price for customers [1][2][5]. Product Launch - The new PRO formula includes significant increases in key nutrients, such as Vitamin B12 (up 733% to 200mcg) and Cell Renewal (up 300% to 100mg), aimed at delivering clinical-grade nutritional impact [3]. - Two new flavors, Mango + Passionfruit and Lemon + Orange, have been introduced to cater to consumer demand for variety [1][4]. Customer Engagement - Daily Ultimate Essentials has received over 10,000 five-star reviews and achieved more than 670,000 customer purchases since its launch, indicating strong market acceptance [2]. - Existing subscribers will be automatically upgraded to the PRO formula at no additional cost, ensuring accessibility for all customers [5]. Nutritional Advancements - The PRO formula features bioactive forms of Vitamin B6 and Riboflavin, enhancing nutrient absorption and utilization [3]. - The addition of saffron extract as a new ingredient aims to support mood and cognitive clarity [3]. Company Overview - Prenetics is a leading health sciences company focused on advancing human health and longevity, with its flagship brand IM8 co-founded by David Beckham [6][7]. - IM8 has rapidly grown, surpassing $100 million in annualized recurring revenue within 11 months and is now available in over 30 countries [6].

Financial Data and Key Metrics Changes - The company achieved record revenue of $92.4 million for the full year 2025, representing a 480% increase year-over-year [4][14] - Fourth quarter revenue surged 457% year-over-year to $36.6 million, with a 55% sequential increase from Q3 [13] - Gross profit in Q4 grew over 800% year-over-year to $21.7 million, with a consolidated gross margin of 59% [13] - Adjusted EBITDA loss for Q4 was $2.3 million, a 70.4% improvement from the same period in the prior year [13][14] - Full year adjusted EBITDA loss improved by 27% to $13 million [14] Business Line Data and Key Metrics Changes - IM8 was the clear driver of revenue, generating $60.1 million for the full year 2025 at a healthy 63% gross margin [14] - IM8 reached a $120 million annualized revenue run rate in its first year, with Q4 revenue of $27.4 million [4][9] - The average order value for new customers more than doubled from $110 in 2025 to approximately $233 in early 2026 [10] Market Data and Key Metrics Changes - 40% of IM8's revenues came from the US, with the remaining 60% from international markets across 30 different countries [10] - The company plans to localize its website in at least five different markets by Q2 2026, expecting a 10%-15% revenue uplift in those markets [47] Company Strategy and Development Direction - The company completed a strategic pivot by divesting non-core assets to focus on becoming a pure-play consumer health leader [5][6] - The balance sheet is strong, with approximately $171 million in total liquidity and zero debt, allowing for investment in IM8's global expansion [8] - The company aims for adjusted EBITDA profitability by Q4 2027, supported by strong unit economics and significant operating leverage [5][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of IM8, with a revenue guidance of $180 million-$200 million for 2026, representing nearly 300% year-over-year growth [15] - The company is excited about launching two new products in Q4 2026, which are expected to enter large total addressable markets [16][26] Other Important Information - The company ceased all Bitcoin purchases as of December 4, 2025, and will not engage in any future Bitcoin or crypto purchases [8] - Research coverage has been initiated by Roth Capital Partners and Sidoti & Company, both with buy ratings and price targets of $36 and $30 respectively [12] Q&A Session Summary Question: Reasoning behind the 90-day offering - Management explained that the quarterly subscription option was well-received by consumers, providing savings and increasing average order value, which shortens the payback period for customer acquisition costs [20][21][22] Question: Timing and nature of new product launches - Two new SKUs are planned for release by the end of Q4 2026, focusing on health and performance supplements, targeting large total addressable markets [26] Question: Revenue guidance and trends - Management confirmed continued momentum in January and stated that new products are not included in the revenue guidance of $180 million-$200 million [27][28] Question: Customer acquisition costs and lifetime values - Customer acquisition costs are approximately $130, with a payback period of 3.4 months, and the average order value has increased significantly [33] Question: Use of AI in marketing - The company utilizes AI for digital marketing, rolling out numerous ads weekly and optimizing based on performance [34][35][36] Question: Strategic M&A strategy - The focus is on organic growth, but the company remains open to strategic M&A opportunities if they align with business goals [39] Question: Revenue growth sources - The majority of growth is expected from acquiring new customers, with significant potential in the US market [45][46]

Financial Data and Key Metrics Changes - The company achieved record revenue of $92.4 million for the full year 2025, representing a 480% increase year-over-year [4] - Fourth quarter revenue surged 457% year-over-year to $36.6 million, with a 55% sequential increase from Q3 [13] - Gross profit for the full year was $48.9 million, an approximately 428% increase, with a consolidated gross margin of 59% in Q4 [13][14] - Adjusted EBITDA loss for the fourth quarter improved by 70.4% year-over-year to $2.3 million, while the full-year adjusted EBITDA loss improved by 27% to $13 million [13][14] Business Line Data and Key Metrics Changes - IM8 was the primary driver of growth, generating $60.1 million in revenue for the full year 2025 at a healthy 63% gross margin [14] - IM8 reached a $120 million annualized revenue run rate within its first year, with Q4 revenue for IM8 at $27.4 million [4][10] - The average order value for new customers more than doubled from $110 in 2025 to approximately $233 in early 2026 [11] Market Data and Key Metrics Changes - 40% of IM8's revenues came from the U.S., with the remaining 60% from international markets across 30 different countries [10] - The company plans to localize its website in at least five different markets by Q2 2026, expecting a 10%-15% revenue uplift in those regions [48] Company Strategy and Development Direction - The company completed a strategic pivot by divesting non-core assets, including the sale of ACT Genomics for $72 million and a 35% stake in Insighta to Tencent for $70 million [5][7] - The focus is on building IM8 into a global consumer health powerhouse, with plans to launch two new products in the health and performance space by the end of Q4 2026 [9][26] - The company aims for adjusted EBITDA profitability by Q4 2027, supported by strong unit economics and significant operating leverage [5][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of IM8, highlighting strong momentum and a clear path to becoming a billion-dollar global brand [16] - The company anticipates continued revenue growth driven primarily by customer acquisition, with significant potential in the U.S. market [45] - Management noted that the new product launches are not included in the current revenue guidance of $180 million-$200 million for 2026 [28] Other Important Information - The company has $171.1 million in total adjusted liquid assets with $0 debt, providing ample runway for investment in IM8's global expansion [8] - The company has ceased all Bitcoin purchases and will not engage in any future crypto purchases, holding 510 BTC for financial flexibility [8] Q&A Session Summary Question: Reasoning behind the 90-day offering - Management explained that the quarterly subscription option was well-received by consumers, providing savings and increasing average order value, which shortens the payback period for customer acquisition costs [20][22] Question: Timing and characteristics of new product launches - Management confirmed plans to release two new SKUs in the health and performance space by the end of Q4 2026, targeting large total addressable markets [26] Question: Trends observed in January and revenue guidance - Management noted continued momentum in January, with new products not included in the revenue guidance of $180 million-$200 million for 2026 [27][28] Question: Customer acquisition costs and lifetime values - Management provided insights on customer acquisition costs and lifetime values, indicating a payback period of approximately 3.4 months and a significant increase in average order value [33] Question: Use of AI in marketing - Management discussed leveraging AI for digital marketing, including ad optimization and content creation, resulting in significant engagement metrics [35][36] Question: Strategic M&A strategy - Management emphasized a focus on organic growth while remaining open to strategic M&A opportunities if they align with the company's goals [39]

Financial Data and Key Metrics Changes - Prenetics achieved record revenue of $92.4 million for the full year 2025, representing a 480% increase year-over-year [4] - Q4 revenue surged 457% year-over-year to $36.6 million, with a 55% sequential increase from Q3 [13] - Gross profit for Q4 grew over 800% year-over-year to $21.7 million, with a consolidated gross margin of 59% [13] - Adjusted EBITDA loss for Q4 was $2.3 million, a 70.4% improvement from the same period in the prior year [13] - Full year adjusted EBITDA loss improved by 27% to $13 million [14] Business Line Data and Key Metrics Changes - IM8 was the primary driver of revenue, generating $60.1 million for the full year 2025 at a gross margin of 63% [14] - IM8 reached a $120 million annualized revenue run rate within its first year, with Q4 revenue from IM8 at $27.4 million [4][9] - The average order value for new customers increased from $110 in 2025 to approximately $233 in early 2026 [11] Market Data and Key Metrics Changes - 40% of IM8's revenues came from the US, while 60% came from international markets across 30 different countries [10] - The company plans to localize its website in at least five different markets by Q2 2026, expecting a revenue uplift of 10%-15% in local markets [46][47] Company Strategy and Development Direction - Prenetics completed a strategic pivot to focus solely on consumer health by divesting non-core assets, enhancing its margin profile and financial position [5][6] - The company aims to achieve adjusted EBITDA profitability by Q4 2027, supported by strong unit economics and significant operating leverage [5][14] - Two new products are expected to launch by the end of Q4 2026, targeting large total addressable markets [25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of IM8, highlighting strong momentum and a clear path to becoming a billion-dollar global brand [16] - The company anticipates continued revenue growth driven primarily by customer acquisition, with significant opportunities in the US and international markets [44] Other Important Information - Prenetics has a total liquidity of approximately $171 million with zero debt, providing ample runway for investment in IM8's global expansion [7] - The company has ceased all Bitcoin purchases and will not engage in any future crypto purchases, holding 510 BTC for financial flexibility [7][8] Q&A Session Summary Question: Reasoning behind the 90-day offering - Management indicated that the quarterly subscription option was well-received by consumers, providing benefits for both sides, including upfront payment and reduced logistics costs [20][21] Question: Timing and characteristics of new product launches - Two new SKUs are planned for release by the end of Q4 2026, focusing on health and performance supplements in large markets [25] Question: Trends observed in January and guidance for IM8 - Management noted continued momentum in January, with new products not included in the revenue guidance of $180 million-$200 million for 2026 [26][27] Question: Customer acquisition costs and lifetime values - Customer acquisition costs are approximately $130, with a payback period of 3.4 months, and the average order value has increased significantly [32][33] Question: Use of AI in marketing - The company utilizes AI for digital marketing, generating a high volume of ads and optimizing performance based on algorithmic feedback [34][35] Question: Strategic M&A strategy - The focus remains on organic growth, with openness to strategic M&A opportunities if they align with the company's goals [38] Question: Revenue growth sources and localization impact - Most growth is expected from new customer acquisition, with localization efforts anticipated to yield a 10%-15% revenue increase in targeted markets [44][46]

Core Insights - Prenetics Global Limited (NASDAQ: PRE) has appointed Formula 1 driver Ollie Bearman as its Global Ambassador and shareholder, enhancing the brand's association with elite athletes committed to health excellence [1][3][8] Company Overview - Prenetics is a leading health sciences company focused on advancing human health and longevity, with its flagship brand IM8 co-founded by David Beckham [11][12] - IM8 has rapidly grown to become one of the fastest-growing supplement brands globally, achieving over US$100 million in Annual Recurring Revenue within just 11 months of its launch [3][11] Product Highlights - IM8's flagship product, Daily Ultimate Essentials, is an all-in-one powder supplement designed to replace 16 different supplements, and is NSF Certified for Sport, ensuring quality and safety for athletes [6][12] - The product is non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors, or sweeteners [12] Athlete Partnership - Ollie Bearman, at just 20 years old, has already made a significant impact in Formula 1, including a historic debut with Ferrari, and has expressed strong belief in IM8's mission and products [5][9] - Bearman experienced notable performance benefits from using IM8's products, which contributed to his decision to invest in the brand [6][7] Market Position - IM8 is sold in over 30 countries worldwide and is backed by a Scientific Advisory Board comprising experts from prestigious institutions like the Mayo Clinic and Cedars-Sinai [9][11]

Core Insights - Natural Health Trends Corp. (NHTC) shares increased by 2.1% following the earnings report for Q4 2025, outperforming the S&P 500 Index, which declined by 0.2% during the same period [1] Financial Performance - For Q4 2025, NHTC reported a revenue decline of 10.1% year-over-year to $9.7 million from $10.8 million, although there was a sequential sales increase of 3% from Q3 [2] - The operating loss widened to $0.6 million from $0.4 million in the prior-year period, and the net loss was $0.6 million, or $0.05 per diluted share, compared to a net income of $0.2 million, or $0.02 per diluted share, in Q4 2024 [2] - For the full year 2025, revenue decreased by 7.4% to $39.8 million from $42.9 million in 2024, with an expanded operating loss of $1.8 million compared to $1.3 million in 2024 [3] Key Business Metrics - Gross profit for Q4 was $7.1 million, down 11.7% from $8 million a year ago, with a gross margin of 73.9%, slightly below 74.2% in the prior-year period [4] - Commissions expense decreased by 13.7% to $3.9 million from $4.5 million in Q4 2024, improving as a percentage of net sales to 40.3% from 41.9% [5] - Active Members declined by 13.7% year-over-year to 26,650 as of Dec. 31, 2025, from 30,870 a year earlier, indicating challenges in distributor engagement [6] Balance Sheet and Cash Flow - Total cash, cash equivalents, and marketable securities were $28.9 million at year-end, down from $32 million as of Sept. 30, 2025 [7] - Net cash used in operating activities was $5.9 million for the full year, compared to $3.4 million in 2024, with $9.2 million paid in dividends during 2025 [7] Management Commentary - Management characterized Q4 2025 results as showing early signs of stabilization despite a challenging macroeconomic environment, highlighting a 3% sequential revenue increase and improved reorder percentages [8] - Growth was noted in markets such as Taiwan and Peru, with Japan and Colombia also showing strong increases throughout the year [8] Strategic Initiatives - Restructuring initiatives significantly influenced quarterly results, including relocating about 40% of product sourcing from America to East Asia to mitigate tariff uncertainties [10] - Restructuring-related charges totaled $283,000 in Q4, and excluding these charges, the operating loss would have been $352,000, indicating some underlying improvement in cost structure [11] Future Outlook - Management anticipates realizing approximately $1.5 million in annualized cost savings from restructuring during 2026, with confidence that cost reductions and anniversary-driven initiatives could enhance performance [12] - A quarterly cash dividend of $0.10 per share was declared, reflecting management's commitment to returning capital to shareholders despite operational challenges [13]

Summary of Prenetics Conference Call Company Overview - **Company Name**: Prenetics - **Ticker**: PRE - **CEO**: Danny Young - **Industry**: Life Sciences and Nutritional Supplements Key Points and Arguments Company Background - Prenetics was co-founded by Danny Young, who has a background in entrepreneurship and e-commerce, notably as the East Asia CEO of Groupon from 2010 to 2014 [2][3] - The company initially focused on DNA testing and pivoted to COVID-19 PCR testing during the pandemic, generating approximately $800 million in revenue and $100 million in net profit [3][4] - Prenetics went public on Nasdaq in 2022 with a valuation of $1 billion, which subsequently declined as COVID testing demand decreased [4] IM8 Brand Launch - In 2023, Prenetics launched IM8, a nutritional supplement brand co-founded with David Beckham, aimed at simplifying nutrition [4][5] - IM8 achieved $60 million in revenue for 2025 and is projected to reach $180 million to $200 million in 2026, with a long-term goal of $350 million to $400 million in 2027 [9][29] Financial Metrics - Prenetics has approximately $110 million in cash and 510 Bitcoin on its balance sheet, with zero debt [6] - The company has a net asset value of about $560 million, including a $380 million valuation for the IM8 business and a $70 million investment in Insighta [21][22] Market Position and Growth - The global supplement market is projected to reach $700 billion by 2030 [13] - IM8 has achieved a $120 million annual recurring revenue (ARR) and is noted for being the fastest supplement brand to reach $100 million ARR in under 12 months [11][12] - The average order value has increased from $110 to $200 due to new product launches and subscription options [34] Customer Engagement and Marketing Strategy - IM8 operates primarily as a direct-to-consumer brand, with 98% of sales through its website [12] - The company has a high customer retention rate, with 80% of customers on monthly or three-month renewal subscriptions [14] - Marketing strategies include leveraging AI for ad creation and targeting, with plans to expand into new channels like YouTube and TikTok [23][26] Product Differentiation - IM8 products are NSF Certified for Sport, ensuring they are free from banned substances, which is crucial for professional athletes [17][32] - The product simplifies supplementation by combining 16 different supplements into one powder, enhancing convenience for users [15][10] Future Outlook - Prenetics plans to invest in new marketing channels, product localization, and partnerships with athletes across various sports to drive growth [22][23] - The company aims to build brand recognition and community engagement, with a goal of becoming one of the world's largest supplement brands within the next three to five years [37][38] Additional Important Information - Prenetics has divested from other business units, focusing primarily on IM8 and its core competencies in nutritional supplements [5][9] - The company has faced challenges due to legacy issues from previous business models, but is optimistic about its growth trajectory and market potential [27][36]